A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1

  Measured over: Up to Cycle 1 (up to 21 days)

• Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

  Measured over: From start of study drug up to 30 days after last dose (up to 3.7 months)

• Phase 1: Number of Participants With Grade 3 or Higher TEAEs by Severity

  Measured over: From start of study drug up to 30 days after last dose (up to 3.7 months)

• Phase 1: Number of Participants With Serious TEAEs

  Measured over: From start of study drug up to 30 days after last dose (up to 3.7 months)

• Phase 1: Number of Participants With TEAEs Leading to Drug Discontinuation

  Measured over: From start of study drug up to 30 days after last dose (up to 3.7 months)

• Phase 1: Number of Participants With TEAEs Leading to Infusion Interruption

  Measured over: From start of study drug up to 30 days after last dose (up to 3.7 months)

• Phase 1: Number of Participants With TEAEs Leading to Dose Delayed

  Measured over: From start of study drug up to 30 days after last dose (up to 3.7 months)

• Phase 1: Number of Participants With TEAEs Leading to Dose Reduction

  Measured over: From start of study drug up to 30 days after last dose (up to 3.7 months)

• Phase 1: Number of Participants With Adverse Event of Clinical Interest (AECIs)

  Measured over: From start of study drug up to 30 days after last dose (up to 3.7 months)

• Phase 2: Objective Response Rate (ORR) Assessed by Investigator With Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

Changes Tremor has spotted